EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, HBM Holdings's Enterprise Value is €-7.48 Mil.
HBM Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €18.95 Mil. Therefore, HBM Holdings's EV-to-FCF for today is -0.39.
The historical rank and industry rank for HBM Holdings's EV-to-FCF or its related term are showing as below:
FRA:6XY'
s EV-to-FCF Range Over the Past 10 Years
Min: -17.19 Med: -0.8 Max: 5.86
Current: -0.25
During the past 6 years, the highest EV-to-FCF of HBM Holdings was 5.86. The lowest was -17.19. And the median was -0.80.
FRA:6XY's EV-to-FCF is ranked better than 98.19% of 387
companies
in the Biotechnology industry
Industry Median: 8.7
vs FRA:6XY: -0.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for HBM Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of HBM Holdings's EV-to-FCF
For the Biotechnology subindustry, HBM Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where HBM Holdings's EV-to-FCF falls into.
HBM Holdings EV-to-FCF Calculation
HBM Holdings's EV-to-FCF for today is calculated as:
HBM Holdings's current Enterprise Value is €-7.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €18.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (FRA:6XY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HBM Holdings's PE Ratio (TTM) for today is calculated as:
HBM Holdings's share price for today is €0.112.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €0.026.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
HBM Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of HBM Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:6XY has been successfully added to your 